Cytokinetics (CYTK) Tops Q4 EPS by 43c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $70.15 +1.27%
EPS Growth %: -45.5%
Financial Fact:
Net loss: 31.89M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: -45.5%
Financial Fact:
Net loss: 31.89M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 basic EPS of $0.16, $0.43 better than the analyst estimate of ($0.27), may not compare. Revenue for the quarter came in at $33.1 million versus the consensus estimate of $16.33 million.
GUIDANCE:
Cytokinetics sees FY 2017 cash revenue of $21-23 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Academy Sports and Outdoor (ASO) Misses Q1 EPS by 1c ; Offers Guidance
- Limoneira (LMNR) Misses Q2 EPS by 8c, Beats on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
